targeting p53 in mds
Published 3 years ago • 76 plays • Length 1:13Download video MP4
Download video MP3
Similar videos
-
4:38
soho 2021 highlights: ‘targeting p53 in mds’
-
1:26
updates in the treatment landscape of p53-mutated aml/mds
-
1:59
depth of molecular response in patients with tp53m mds & aml treated with magrolimab and azacitidine
-
1:08
novel strategies to target p53-mutant hematological malignancies
-
1:38
the importance of targeting tp53 in aml and agents being explored
-
1:33
the current guidelines and therapies for tp53-mutated mds and aml
-
1:38
the role and targeting of immune dysregulation in mds
-
5:16
an analysis of tp53 mutation in aml and hr-mds
-
3:13
[proav lab] 3minav - what is ndi? | lumens proav
-
7:51
replacing ink filter m022219 on the mimaki ujf-6042mkii / ujf-3042mkii.
-
8:14
progress in the treatment of tp53 mutated aml
-
1:04
mp0533, a cd3-engaging darpin, in r/r aml or mds/aml: preliminary results of a phase i/iia trial
-
2:35
methods of optimizing transplantation in mds
-
2:24
the challenges of treating tp53-mutated aml and mds
-
2:26
impact of allelic state on os in tp53-mutant aml and hr-mds
-
1:51
checkpoint inhibition in the treatment of mpns
-
3:00
apr-246 in tp53 mutated mds and aml
-
2:23
improving treatment for patients with tp53-mutated myeloid malignancies
-
1:23
immunological impact of tp53 in mds
-
1:21
hmas for mds- a party of one
-
0:58
options available to patients with tp53-mutated mds beyond stem cell transplantation
-
3:14
apr-246 with azacitidine for p53 mutated mds and aml